Volume 12, Issue 2 (Vol.12 No.2 Jul 2023)                   rbmb.net 2023, 12(2): 220-232 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kamil Alhassbalawi N, Zare Ebrahimabad M, Seyedhosseini F S, Bagheri Y, Abdollahi N, Nazari A, et al . Circulating miR-21 Overexpression Correlates with PDCD4 and IL-10 in Systemic Lupus Erythematosus (SLE): A Promising Diagnostic and Prognostic Biomarker. rbmb.net 2023; 12 (2) :220-232
URL: http://rbmb.net/article-1-1195-en.html
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran & Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract:   (1338 Views)
Background:  Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition that affects multiple organs significantly impacts morbidity and mortality. The development of SLE is influenced by genetic predisposition and dysregulated immune response. Our objective was to investigate miR-21, IL-10, and PDCD4 expression in SLE patient plasma and analyze their correlations and potential diagnostic and prognostic values.

Methods: The study included 100 healthy subjects, 50 newly diagnosed (ND), and 50 under-treatment (UT) SLE patients. The patients were observed for 24 weeks to track relapses. miR-21 and PDCD4 gene expression levels were measured using real-time RT-PCR, and IL-10 production was measured using ELISA.

Results: miR-21 and IL-10 expression levels were significantly greater in SLE patients than in healthy subjects, with the highest levels observed in ND patients. PDCD4 expression was also significantly greater in SLE patients than in subjects, with the highest levels observed in UT patients. ROC curve analyses and Cox-Mantel Log-rank tests indicated miR-21, PDCD4, and IL-10 as proper diagnostic and prognostic biomarkers for SLE. The study also revealed a significant positive correlation between miR-21 and PDCD4 and IL-10 levels in SLE patients.

Conclusions: The studies suggest that dysregulation of miR-21, PDCD4, and IL-10 in patients with SLE may contribute to disease development and provides new diagnostic and prognostic markers. Additionally, the observed correlation between miR-21, PDCD4, and IL-10 levels in SLE patients signifies a potential interplay between these molecules.
Full-Text [PDF 521 kb]   (594 Downloads)    
Type of Article: Original Article | Subject: Immunology
Received: 2023/06/19 | Accepted: 2023/07/11 | Published: 2023/12/20

References
1. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. The Lancet. 2019;393(10188):2344-58. [DOI:10.1016/S0140-6736(19)30546-X] [PMID]
2. Danchenko N, Satia J, Anthony M. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18. [DOI:10.1191/0961203306lu2305xx] [PMID]
3. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS, editors. Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in arthritis and rheumatism; 2010: Elsevier. [DOI:10.1016/j.semarthrit.2008.10.007] [PMID] []
4. Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol. 2013;148(3):359-68. [DOI:10.1016/j.clim.2012.09.009] [PMID] []
5. Eghbalpour F, Aghaei M, Ebrahimi M, Tahsili MR, Golalipour M, Mohammadi S, Yazdani Y. Effect of indole- 3- carbinol on transcriptional profiling of wound-healing genes in macrophages of systemic lupus erythematosus patients: an RNA sequencing assay. Lupus. 2020;29(8):954-63. [DOI:10.1177/0961203320929746] [PMID]
6. Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15(2):200-205. [DOI:10.1016/j.gde.2005.01.002] [PMID]
7. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3-14. [DOI:10.1016/j.addr.2015.05.001] [PMID] []
8. Ibrahim SA, Afify AY, Fawzy IO, El-Ekiaby N, Abdelaziz AI. The curious case of miR-155 in SLE. Expert Rev Mol Med. 2021;23:e11. [DOI:10.1017/erm.2021.11] [PMID]
9. Omidi F, Khoshmirsafa M, Kianmehr N, Faraji F, Delbandi A, Seif F, Shekarabi M. Comparison of circulating miR-148a and miR-126 with autoantibodies as biomarkers of lupus nephritis in patients with SLE. J Immunoass Immunochem. 2022;43(6):634-47. [DOI:10.1080/15321819.2022.2099225] [PMID]
10. Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal. 2013;25(9):1828-36. [DOI:10.1016/j.cellsig.2013.05.006] [PMID]
11. Nakhjavani M, Etemadi J, Pourlak T, Mirhosaini Z, Zununi Vahed S, Abediazar S. Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis. Iran J Kidney Dis. 2019;13(3):198-206.
12. Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35-48. [DOI:10.1016/j.canlet.2021.06.009] [PMID]
13. Yazdani Y, Sadeghi H, Alimohammadian M, Andalib A, Moazen F, Rezaei A. Expression of an innate immune element (mouse hepcidin-1) in baculovirus expression system and the comparison of its function with synthetic human hepcidin-25. Iran J Pharm Res. 2011;10(3):559-68.
14. Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res. 1999;48(5):255-61. [DOI:10.1007/s000110050456] [PMID]
15. Wu YR, Hsing CH, Chiu CJ, Huang HY, Hsu YH. Roles of IL-1 and IL-10 family cytokines in the progression of systemic lupus erythematosus: Friends or foes? IUBMB Life. 2022;74(2):143-156. [DOI:10.1002/iub.2568] [PMID]
16. Mohammadi S, Saghaeian Jazi M, Zare Ebrahimabad M, Eghbalpour F, et al. Interleukin 10 gene promoter polymorphisms (rs1800896, rs1800871 and rs1800872) and haplotypes are associated with the activity of systemic lupus erythematosus and IL10 levels in an Iranian population. Int J Immunogenet. 2019;46(1):20-30. [DOI:10.1111/iji.12407] [PMID]
17. Geginat J, Vasco M, Gerosa M, Tas SW, Pagani M, Grassi F, et al., editors. IL-10 producing regulatory and helper T-cells in systemic lupus erythematosus. Semin Immunol. 2019;44(101330). [DOI:10.1016/j.smim.2019.101330] [PMID]
18. Wang X, Li Y, Wan L, Liu Y, Sun Y, Liu Y, Shi Y, et al. Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells. Oncol Rep. 2019;42(2):849-56. [DOI:10.3892/or.2019.7202] [PMID]
19. Wang L, Zhao M, Guo C, Wang G, Zhu F, Wang J, et al. PDCD4 Deficiency Aggravated Colitis and Colitis-associated Colorectal Cancer Via Promoting IL-6/STAT3 Pathway in Mice. Inflamm Bowel Dis. 2016;22(5):1107-18 [DOI:10.1097/MIB.0000000000000729] [PMID]
20. Mohammadi S, Sedighi S, Memarian A, Yazdani Y. Overexpression of interferon-γ and indoleamine 2, 3-dioxygenase in systemic lupus erythematosus: relationship with the disease activity. Lab Med 2017; 41(1): 41-47. [DOI:10.1515/labmed-2016-0076]
21. Ahearn JM, Liu CC, Kao AH, Manzi S. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159(4):326-42. [DOI:10.1016/j.trsl.2012.01.021] [PMID]
22. Castro-Leyva V, Arenas-Huertero F, Espejel-Núñez A, Giono Cerezo S, Flores-Pliego A, Espino YSS, et al. miR-21 differentially regulates IL-1β and IL-10 expression in human decidual cells infected with streptococcus B. Reprod Biol. 2022;22(1):100604. [DOI:10.1016/j.repbio.2022.100604] [PMID]
23. Jiang LH, Ge MH, Hou XX, Cao J, Hu SS, Lu XX, et al. miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma. Lab Invest. 2015;95(12):1398-408. [DOI:10.1038/labinvest.2015.105] [PMID]
24. Bragato JP, Rebech GT, Freitas JH, Santos MOD, Costa SF, Eugênio FR, et al. miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis. PLoS One. 2022;17(3):e0265192. [DOI:10.1371/journal.pone.0265192] [PMID] []
25. Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011;70(8):1496-506. [DOI:10.1136/ard.2010.139857] [PMID]
26. Roohi A, Yazdani Y, Khoshnoodi J, Jazayeri SM, Carman WF, Chamankhah M, et al. Differential reactivity of mouse monoclonal anti-HBs antibodies with recombinant mutant HBs antigens. World J Gastroenterol. 2006;12(33):5368-74. [DOI:10.3748/wjg.v12.i33.5368] [PMID] []
27. Jazi MS, Mohammadi S, Yazdani Y, Sedighi S, Memarian A, Aghaei M. Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells. Iran J Basic Med Sci. 2016;19(7):779-86.
28. Nakhjavani M, Etemadi J, Pourlak T, Mirhosaini Z, Zununi Vahed S, Abediazar S. Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis. Iran J Kidney Dis. 2019;13(3):198-206.
29. Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011;70(8):1496-506. [DOI:10.1136/ard.2010.139857] [PMID]
30. Tang ZM, Fang M, Wang JP, Cai PC, Wang P, Hu LH. Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients. J Clin Lab Anal. 2014;28(6):446-51. [DOI:10.1002/jcla.21708] [PMID] []
31. Kourti M, Sokratous M, Katsiari CG. Regulation of microRNA in systemic lupus erythematosus: the role of miR-21 and miR-210. Mediterr J Rheumatol. 2020;31(1):71-74. [DOI:10.31138/mjr.31.1.71] [PMID] []
32. Khoshmirsafa M, Kianmehr N, Falak R, Mowla SJ, Seif F, Mirzaei B, et al. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. Int J Rheum Dis. 2019;22(3):458-467. [DOI:10.1111/1756-185X.13410] [PMID]
33. Cai Q, Yang HS, Li YC, Zhu J. Dissecting the Roles of PDCD4 in Breast Cancer. Front Oncol. 2022;12:855807. [DOI:10.3389/fonc.2022.855807] [PMID] []
34. El Gedawy G, Obada M, Kelani A, El-Said H, Ghanayem NMJEjomhg. Circulating MiRNA-21 and programed cell death (PDCD) 4 gene expression in hepatocellular carcinoma (HCC) in Egyptian patients. Egypt J Med Hum Genet. 2017;18(2):137-45. [DOI:10.1016/j.ejmhg.2016.04.007]
35. S Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, et al. Micro RNA analysis reveals novel genes in human systemic lupus erythematosus: miR-21affects PDCD4 expression and regulates aberrant T cell responses. Ann Rheum Dis. 2011;70(8):1496-506. [DOI:10.1136/ard.2010.139857] [PMID]
36. Garchow BG, Bartulos Encinas O, Leung YT, Tsao PY, Eisenberg RA, Caricchio R, et al. Silencing of microRNA‐21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO molecular medicine. EMBO Mol Med. 2011;3(10):605-15. [DOI:10.1002/emmm.201100171] [PMID] []
37. Rahmati M, Ferns GA, Mobarra N. The lower expression of circulating miR-210 and elevated serum levels of HIF-1α in ischemic stroke; Possible markers for diagnosis and disease prediction. J Clin Lab Anal. 2021;35(12):e24073. [DOI:10.1002/jcla.24073] [PMID] []
38. Zheng X, Zhang Y, Yue P, Liu L, Wang C, Zhou K, et al. Diagnostic significance of circulating miRNAs in systemic lupus erythematosus. PLoS One. 2019;14(6):e0217523. [DOI:10.1371/journal.pone.0217523] [PMID] []
39. Tangtanatakul P, Klinchanhom S, Sodsai P, Sutichet T, Promjeen C, Avihingsanon Y, Hirankarn N. Down-regulation of let-7a and miR-21 in urine exosomes from lupus nephritis patients during disease flare. Asian Pac J Allergy Immunol. 2019;37(4):189-197.
40. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27(5):461-6. [DOI:10.1007/s10875-007-9104-0] [PMID]
41. Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand EF, Harris J. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep. 2016; 6:34604. [DOI:10.1038/srep34604] [PMID] []
42. Hu C, Zhou J, Yang S, Li H, Wang C, Fang X, et al. Oxidative stress leads to reduction of plasmalogen serving as a novel biomarker for systemic lupus erythematosus. Free Radic Biol Med. 2016;101:475-481. [DOI:10.1016/j.freeradbiomed.2016.11.006] [PMID]
43. Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021;13(4):2867-2874.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb